Atlanta, Georgia and Montgomery, Alabama, 1 January 2024

We are thrilled to announce exclusive license agreement with Alabama State University for a novel anti-respiratory syncytial virus (RSV) therapeutics. RSV causes bronchiolitis and severe lower respiratory tract infections in infants leading to nearly 50,000–80,000 hospitalization among U.S. infants and children under the age of 5; most children are infected during the first year of life, and nearly all have been infected by age 2 years. It can also cause severe infections in elderly and immunocompromised. Unfortunately, there is no approved treatment for infants and children, or elderly.

ARNV-F2 (tentatively named), is a fusion inhibitor that blocks the fusion of RSV to host cells, thus, halting infection.

With this agreement ARNAV will be uniquely positioned to move this drug quickly to the pre-IND and IND enabling studies. Dr. Shree Ram Singh, inventor of this drug, at Alabama State University and   Co-founder and CEO or ARNAV Biotech said in a statement, “This licensing agreement is a significant milestone in ARNAV’s business model which enables us to take the anti-RSV innovation to the marketplace. With our strong technological capabilities, we are able to bring the product to treat RSV disease which has become a significant health issue since the COVID pandemic”.

Dr. Pooja M. Tiwari, co-inventor of this drug and COO at ARNAV Biotech said, “I am thrilled to see what we develop as my Ph. D. project move one step closer from bench to the bedside. As a mother of a young child, I always worried whether the virus I studied for so long, affect my child or anyone else. Luckily, we were saved from RSV, but there are thousands of infants and young children and even elderly, suffering from RSV related complications. This brings hope to parents and caregivers like me to have something to treat severe RSV infections, hopefully very soon. We are looking for partners to advance the clinical development of this drug”.

For investment or collaboration opportunities please email: info@arnavbiotech.com

For more information visit: www.arnavbiotech.com

About Alabama State University: Alabama State Universitys is a public historically black university (HBCU) in Montgomery, Alabama. Founded in 1867, during the Reconstruction era, it was one of about 180 “normal schools” established by state governments in the 19th century to train teachers for the rapidly growing public common schools. Some of the 180 closed but most steadily expanded their role and became state colleges in the early 20th century and state universities in the late 20th century. ASU is a member-school of the Thurgood Marshall College Fund.

About Arnav Biotech: ARNAV Biotech is an Atlanta, US based mRNA therapeutics and CDRMO developing anti-viral therapeutics, mRNA based broad-spectrum antivirals, mRNA-based vaccines, and other therapeutic modalities as well lipid and other nanoparticle delivery vehicles.  For more information, please contact us at info@arnavbiotech.com or visit www.arnavbiotech.com.